Zenith Epigenetics
  • About
  • Science & Epigenetics
  • Programs
  • Newsroom
  • Contact
  • Connect
    Email
    info@zenithepigenetics.com
    Call
    1 (587) 390-7865
    Share
  • FAQ
Newsroom
  • News Releases
  • Presentations & Events
  • SEDAR Filings

News Releases

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
Zenith Epigenetics Announces Clinical Advancement of ZEN-3694
December 19, 2019
Zenith Announces Voting Results from the 2019 Annual and Special Meeting of Shareholders
October 31, 2019
Zenith Announces Annual and Special Meeting of Shareholders
August 22, 2019
Zenith Epigenetics and China-Based Newsoara Biopharma Announce Licensing Agreement for ZEN-3694
August 6, 2019
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
June 27, 2019
Zenith Epigenetics Announces U.S. FDA Clearance of Investigational New Drug Application for ZEN-3694 in TNBC Program
March 18, 2019

About

  • Overview
  • Management
  • Board of Directors

Science & Epigenetics

  • What is Epigenetics?
  • BET Inhibitors & Oncology
    • Resistance & Combo Therapy
  • BET Inhibitor Platform
    • Covalent BET Inhibitors
    • Translational Medicine
  • Publications & Posters

Programs

  • Oncology Pipeline
    • Prostate Cancer
    • Breast Cancer
    • Ovarian Cancer
    • Lung Cancer
    • Other Solid Tumor Cancers
  • Partnerships & Collaborations

Newsroom

  • News Releases
  • Presentations & Events
  • SEDAR Filings

Contact

  • Contact
  • Careers
  • Shareholder FAQ

© 2025 zenithepigenetics | Legal | Privacy

Bookmark and Share